Indian pharma faces multiple regulatory questions in 2013

01/3/2013 | Business Standard (India)

Indian drugmakers are facing several regulatory challenges this year, including the proposed introduction of a bill to monitor the relationship between medical practitioners and drugmakers, the issue of foreign direct investment in brownfield pharma and the Supreme Court's final ruling on the National Pharmaceutical Pricing Policy. Drugmakers also may reconsider their product portfolios and business strategies in light of patent expiries in the U.S. and other developed markets as well as increasing generic penetration.

View Full Article in:

Business Standard (India)

Published in Brief: